

New Dairy Products and Value Chains PGP Programme

Summary Report for Third Quarter 2014-15

A request to extend the delivery of work until 30 June 2016 and increase PGP investment by \$175,000, matched by an equivalent investment by the industry partners, was submitted to the PGP Independent Advisory Panel during this quarter. The requested extension will allow the completion of delayed milestones and the delivery of additional work recommended by the mid-term review. This additional work will extend efficacy and processing studies.

Two in-vivo efficacy trials have been completed and preliminary results indicate that one of the target compounds has been able to suppress the population of a specific pathogenic bacterium in the gut of mice. This is an important finding from the perspective of future marketing activities.

Good progress has been made during this quarter in engaging with potential marketing partners. There is interest in supplying test samples to two companies; and there is ongoing discussion about the science of the target compounds with two other companies. These engagements have been most useful in identifying the necessary information that will be required for successful commercialization.